Autolomous, Center for Breakthrough Medicines Reach Data Visibility Deal
Agreement focused on streamlining and automating manufacturing of cell and gene therapies
Autolomous, a UK developer of manufacturing management systems for cell and gene therapies (CGTs), has inked a license agreement with Center for Breakthrough Medicines, a CGT contract development and manufacturing organization. The arrangement enables Autolomous to create solutions through AutoloMATE, the company’s digital platform that provides connectivity through all manufacturing operations of the CGT value chain.
According to Alexander Seyf, CEO of Autolomous, applying new manufacturing insights and learnings is becoming more critical as the manufacturing demands associated with CGTs accelerate. He says that through this deal, Autolomous will support CBM, which he claims is the world’s largest single CGT manufacturing site, “to enable a digital-first manufacturing platform.”
Autolomous will support Philadelphia-based CBM by converting all batch record views to electronic. The two parties hope this will help consolidate the integration with other systems to provide centralized data visibility. As a result, executives say, CBM will be able to enhance operational learnings, streamline compliance response times, and offer shorter investigation timelines. They believe this will translate to lower costs of goods, higher productivity, and greater manufacturing scalability for CBM clients.
"Partnering with Autolomous allows CBM to digitize our entire supply chain ecosystem and ensures transparency throughout the process while also providing end-to-end data integrity, complete quality assurance and control, and the automation of key parts of the manufacturing process, such as running calculations and transcribing data from batch manufacturing records (BMRs)," comments Jeet Sarkar, VP, head of IT at CBM.
Read more about the deal here.
